A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood
L. Wiren et al., A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood, J CLIN END, 86(8), 2001, pp. 3494-3498
Some patients given growth-promoting therapy for GH deficiency in childhood
will remain GH deficient in their adult lives and hence could benefit from
continued GH replacement therapy. This longitudinal study sought to assess
whether quality of life declines after GH discontinuation in late adolesce
nce, and whether differences can be discerned in quality of life in patient
s whose GH deficiency persists into adulthood and those whose GH secretory
capacity falls within normal ranges. Forty patients, aged 16-21 yr at basel
ine, were assessed over a 2-yr period commencing with discontinuation of GH
therapy. Twenty-one patients were assigned to a GH deficiency group, and 1
9 were assigned to a GH-sufficient group. Quality of life assessments were
made using the Nottingham Health Profile, Psychological General Well-Being
Index, and Mood Adjective Check List Measures. Visual analog assessment of
personality and affect and cognitive function tests were performed. The Moo
d Adjective Check List and visual analog assessments identified between-gro
up and temporal changes in a limited number of the various personality doma
ins assessed. The Psychological General Well-Being Index assessment indicat
ed greater baseline impairment in the GH deficiency group than in the GH-su
fficient group in overall score and in the domains of depression and genera
l health. There was also a between-group difference in anxiety score at the
2-yr assessment, with the GH deficiency group having greater anxiety. Meas
urement of cognitive factors failed to reveal differences between groups.
These results indicate that the discontinuation of GH therapy in late adole
scence does not risk an immediate decline in the perceived quality of life
detectable with the Nottingham Health Profile and Psychological General Wel
l-Being Index measures. However, differences detected with the Mood Adjecti
ve Check List and visual analog assessments hint at clinically significant
changes in the life experiences of adolescents discontinued from GH for whi
ch traditional measures may lack sensitivity.